ÐÂÎÅÖÐÐÄ
News Center
bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾¿âĪÎ÷Àû½ºÄÒ£¨Èü̹ÐÀ?£©µÇ¹ú¼ÊÆÚ¿¯¡¶STTT¡·£¨IF£º52.7£©£¬£¬£¬£¬£¬£¬ÒýÁìÈéÏÙ°©ÄÚÉø͸°ÐÏòÖÎÁÆÉý¼¶ÓÅ»¯
Ðû²¼Ê±¼ä£º2025-12-23
È«ÇòÊ׸öCDK2/4/6ÒÖÖƼÁ¿âĪÎ÷Àû½ºÄÒ£¨Èü̹ÐÀ®£©ÔÙ´«Ï²Ñ¶£¡¼ÌÕýʽ»ñÅúÉÏÊÐÖ®ºó£¬£¬£¬£¬£¬£¬12ÔÂ17ÈÕ£¬£¬£¬£¬£¬£¬Èü̹ÐÀ®ÍŽá·úά˾ȺÖÎÁƾÖεļ¤ËØÊÜÌåÑôÐÔ¡¢È˱íƤÉú³¤Òò×ÓÊÜÌå2ÒõÐÔ£¨HR+/HER2-£©ÍíÆÚÈéÏÙ°©µÄÒ»ÏîËæ»ú¡¢Ë«Ã¤¡¢¢óÆÚÁÙ´²ÊÔÑéÑо¿£¬£¬£¬£¬£¬£¬Õýʽ½ÒÏþÓÚ¡¶Nature¡·×Ó¿¯¡¶Signal Transduction and Targeted Therapy¡·£¨STTT£¬£¬£¬£¬£¬£¬IF£º52.7£©¡£¡£¡£¡£¡£¡£Ñо¿Ð§¹û[1]ÏÔʾ£¬£¬£¬£¬£¬£¬½ÓÊܱ¾¼Æ»®ÖÎÁÆ»¼ÕßµÄÖÐλÎÞÏ£ÍûÉúÑÄÆÚ£¨mPFS£©´ï16.6¸öÔ£¬£¬£¬£¬£¬£¬¼²²¡Ï£Íû»òéæÃüΣº¦Ïà½ÏÓÚ±ÈÕÕ×éÏÔÖø½µµÍ64%¡£¡£¡£¡£¡£¡£
mPFS´ï16.6¸öÔ£¬£¬£¬£¬£¬£¬¼²²¡Ï£Íû/éæÃüΣº¦½µµÍ64%
±¾Ñо¿ÎªÒ»ÏîËæ»ú¡¢Ë«Ã¤¡¢Æ½ÐбÈÕÕ¡¢¢óÆÚÁÙ´²Ñо¿£¬£¬£¬£¬£¬£¬ÓÉÖйú½â·Å¾ü×ÜÒ½ÔºµÚÎåҽѧÖÐÐĽÔó·É½ÌÊںͽËÕÊ¡ÈËÃñÒ½ÔºÒóӽ÷½ÌÊÚÅäºÏµ£µ±Leading PI¡£¡£¡£¡£¡£¡£Ö÷ÒªÑо¿ÖÕµãΪÑо¿ÕßÆÀ¹ÀµÄÎÞÏ£ÍûÉúÑÄÆÚ£¨INV-PFS£©£¬£¬£¬£¬£¬£¬´ÎÒªÑо¿ÖÕµãΪ×ÔÁ¦ÆÀÉóίԱ»áÆÀ¹ÀµÄÎÞÏ£ÍûÉúÑÄÆÚ£¨IRC-PFS£©¡¢×ÜÉúÑÄÆÚ£¨OS£©¡¢¿Í¹Û»º½âÂÊ£¨ORR£©¡¢ÁÙ´²»ñÒæÂÊ£¨CBR£©¼°»º½âÒ»Á¬Ê±¼ä£¨DOR£©µÈ¡£¡£¡£¡£¡£¡£
2022Äê3ÔÂ18ÈÕÖÁ2023Äê3ÔÂ3ÈÕʱ´ú£¬£¬£¬£¬£¬£¬¹²293Àý»¼ÕßÇкÏÌõ¼þÈë×é¡£¡£¡£¡£¡£¡£Èë×黼ÕßµÄÖÐλÄêËêΪ53Ë꣬£¬£¬£¬£¬£¬¼ÈÍù¾ù½ÓÊܹýÄÚÉø͸ÖÎÁÆ£¬£¬£¬£¬£¬£¬23.3%Òò¸´·¢»òתÒÆÐÔ¼²²¡½ÓÊܹýÈ«Éí»¯ÁÆ£¬£¬£¬£¬£¬£¬21.5%µÄ»¼ÕßΪԷ¢ÐÔÄÚÉø͸ÄÍÒ©£¬£¬£¬£¬£¬£¬59%µÄ»¼Õß±£´æÄÚÔàתÒÆ¡£¡£¡£¡£¡£¡£Èë×黼Õß°´2:1µÄ±ÈÀý½ÓÊÜ¿âĪÎ÷ÀûÍŽá·úά˾Ⱥ»òο½å¼ÁÍŽá·úά˾ȺÖÎÁÆ£¬£¬£¬£¬£¬£¬Á½×éÔÚÉú³ÝѧºÍ»ùÏßÌØÕ÷·½Ãæ×ÜÌåƽºâ¡£¡£¡£¡£¡£¡£
×èÖ¹±¾´Î±¨¸æµÄÆÚÖÐÆÊÎö£¬£¬£¬£¬£¬£¬¹²±¬·¢ÁË134ÀýPFSÊÂÎñ£¨ÊÔÑé×é68Àý£¬£¬£¬£¬£¬£¬±ÈÕÕ×é66Àý£©¡£¡£¡£¡£¡£¡£¿âĪÎ÷Àû×émPFSΪ16.6¸öÔ£¨95%CI£º13.8-NE£©£¬£¬£¬£¬£¬£¬±ÈÕÕ×éΪ7.5¸öÔ£¨95%CI£º5.3-11£©£¬£¬£¬£¬£¬£¬HRֵΪ0.36£¨95%CI£º0.26-0.51£¬£¬£¬£¬£¬£¬p<0.001£©¡£¡£¡£¡£¡£¡£PFSÑÇ×éÆÊÎöЧ¹ûÌáÐÑ£¬£¬£¬£¬£¬£¬ËùÓÐÑÇ×é¾ù¿É´Ó¿âĪÎ÷ÀûÖÎÁÆÖлñÒæ¡£¡£¡£¡£¡£¡£
INVÆÀ¹ÀµÄPFSÇúÏßͼ
PFSÑÇ×éÆÊÎö
ÖÐλËæ·Ãʱ¼äΪ13.8¸öÔ£¬£¬£¬£¬£¬£¬´ËʱÁ½×éµÄÖÐλ×ÜÉúÑÄÆÚ£¨mOS£©¾ùδµÖ´ï¡£¡£¡£¡£¡£¡£18¸öÔÂOSÂÊ·½Ã棬£¬£¬£¬£¬£¬¿âĪÎ÷Àû×é±ÈÕÕο½å¼Á×éΪ79.0% vs. 73.9%£¨p=0.188£©¡£¡£¡£¡£¡£¡£¿£¿£¿ £¿£¿£¿âĪÎ÷Àû×éORRΪ40.2%£¨95% CI£º33.3–47.5£©£¬£¬£¬£¬£¬£¬±ÈÕÕ×éΪ12.1%£¨95% CI£º6.4–20.2£©¡£¡£¡£¡£¡£¡£
%20%E6%8B%B7%E8%B4%9D(1).png/640%20(5)%20%E6%8B%B7%E8%B4%9D(1)__600x342.png)
Çå¾²ÐÔ·½Ã棬£¬£¬£¬£¬£¬ÊÔÑé×éÓë±ÈÕÕ×éÖÎÁÆʱ´úµÄ²»Á¼ÊÂÎñ£¨TEAE£©±¬·¢ÂÊÏà½ü£¨98.5% vs. 96.0%£©¡£¡£¡£¡£¡£¡£¿£¿£¿ £¿£¿£¿âĪÎ÷Àû×é³£¼ûTEAEÖ÷ҪΪ¸¹Ðº£¨87.1%£©£¬£¬£¬£¬£¬£¬ÖÐÐÔÁ£Ï¸°ûïÔÌ£¨80.4%£©£¬£¬£¬£¬£¬£¬°×ϸ°ûïÔÌ£¨79.9%£©µÈ£¬£¬£¬£¬£¬£¬Î´±¬·¢·Î˨ÈûºÍ¼äÖÊÐԷβ¡µÈÑÏÖز»Á¼ÊÂÎñ£¬£¬£¬£¬£¬£¬Ïà¹ØÓÚÆäËûCDK4/6ÒÖÖƼÁδ¼ûеÄÇå¾²Ðźš£¡£¡£¡£¡£¡£
±¾Ñо¿ÏÔʾ£¬£¬£¬£¬£¬£¬¿âĪÎ÷ÀûÍŽá·úά˾ȺÄܹ»ÏÔÖøÑÓÉìÄÚÉø͸¾ÖÎÄÍÒ©HR+/HER2−ÍíÆÚÈéÏÙ°©»¼ÕßµÄÎÞÏ£ÍûÉúÑÄÆÚ£¬£¬£¬£¬£¬£¬¼²²¡Ï£Íû»òéæÃüΣº¦½µµÍ64%£¬£¬£¬£¬£¬£¬ÇÒÔÚ¸÷ÑÇ×éÖоùÌåÏÖ³öÒ»ÖµÄÁÆЧÓÅÊÆ£¬£¬£¬£¬£¬£¬¾ß±¸ÏÔÖøÁÙ´²»ñÒæ¡£¡£¡£¡£¡£¡£Í¬Ê±£¬£¬£¬£¬£¬£¬¿âĪÎ÷ÀûµÄ²»Á¼·´Ó¦×ÜÌå¿É¿Ø£¬£¬£¬£¬£¬£¬Î´·ºÆðеÄÇå¾²Ðźš£¡£¡£¡£¡£¡£
×÷ΪȫÇòÊ׿îCDK2/4/6ÒÖÖƼÁ£¬£¬£¬£¬£¬£¬Èü̹ÐÀ®ÕýÔÚÍíÆÚÈéÏÙ°©²î±ðÖÎÁƽ׶ÎÕ¹ÏÖÓ¦ÓÃÔ¶¾°¡£¡£¡£¡£¡£¡£12ÔÂ11ÈÕ£¬£¬£¬£¬£¬£¬¿âĪÎ÷Àû½ºÄÒ£¨Èü̹ÐÀ®£©ÊÕµ½Ò©Æ·×¢²áÅú¼þ£¬£¬£¬£¬£¬£¬ÍŽá·úά˾ȺÓÃÓÚ¼ÈÍù½ÓÊÜÄÚÉø͸¾ÖεÄHR+/HER2-¾Ö²¿ÍíÆÚ»òתÒÆÐÔÈéÏÙ°©ÖÎÁÆ£»£»£» £» £»£»£»½ñÄê7Ô£¬£¬£¬£¬£¬£¬¿âĪÎ÷ÀûÍŽá·úά˾ȺÓÃÓÚHR+/HER2-µÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔÈéÏÙ°©»¼Õß³õʼÄÚÉø͸ÖÎÁƵÄ˳Ӧ֢ÔÙ»ñCDEÊÜÀí¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
[1] Yin Y,et al. Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. Signal Transduct Target Ther. 2025;10(1):414. Published 2025 Dec 18.
ÉùÃ÷£º
1. ±¾ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬£¬£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬£¬£¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£¡£
2. ±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£¡£
3. ±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬£¬£¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬£¬£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬£¬°üÀ¨Óйء¾¿âĪÎ÷Àû½ºÄÒ£¨Èü̹ÐÀ®£©¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬£¬£¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÐÅÍД¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû£¬£¬£¬£¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ï죬£¬£¬£¬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦£¬£¬£¬£¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬£¬£¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£¡£¡£¡£